ANEUVO präsentiert wegweisendes Neuromodulationssystem ExaStim® auf der MEDICA 2024
November 06, 2024 04:00 ET
|
AKAMPION
Neuartiges Produkt mit FDA Breakthrough Device Designation zur Behandlung chronischer RückenmarksverletzungenTechnologie wird in Halle 10 / H44 vorgestellt Düsseldorf, Deutschland – 6....
AMYRA Successfully Demonstrates a New Therapeutic Paradigm for Gluten-Related Disorders in a First-in-Human Study
October 23, 2024 04:00 ET
|
AKAMPION
Lead product AMYNOPEP achieves proof-of-principle in exploratory clinical studyAMYNOPEP is the first and only gluten-digesting enzyme combination that supports and enhances the activity of critical...
Preliminary Data of BellaSeno’s Clinical Trial on Scaffold-Guided Breast Regeneration Presented at the 93rd Annual Plastic Surgery Meeting in San Diego, CA
October 09, 2024 04:00 ET
|
AKAMPION
Performance: Statistically significant superiority over fat grafting, with breast volume retention twice as highSafety: BellaSeno’s scaffolds are safe and improve patient satisfaction and well-being ...
Mabylon AG Receives Research Grants Totaling More Than CHF 1.3 Million for Amyotrophic Lateral Sclerosis (ALS) and Inflammasome Programs
September 24, 2024 04:00 ET
|
AKAMPION
Schlieren, Zurich/Switzerland, September 24, 2024 - Mabylon AG, a leader in the high-throughput discovery, characterization, and development of human-derived antibodies, today announced that it has...
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
September 17, 2024 04:00 ET
|
AKAMPION
Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers ...
ImmunOs Therapeutics Expands Phase I Clinical Trial of IOS-1002 in Combination with KEYTRUDA® (pembrolizumab) for the Treatment of Solid Tumors
July 24, 2024 04:00 ET
|
AKAMPION
Dosing of patients in new combination treatment arm – IOS-1002 plus KEYTRUDA Schlieren (Zurich Area), Switzerland – July 24, 2024 – ImmunOs Therapeutics AG, a biopharmaceutical company using its...
BellaSeno Reports Positive Interim Findings of Australian Clinical Trials in Breast Scaffold Patients
June 12, 2024 04:00 ET
|
AKAMPION
Favorable safety profile of resorbable breast scaffolds in one-year follow-upNo major scaffold-related complications or scaffold removals BellaSeno will initiate multicenter pivotal clinical trial...
Thermosome Appoints Dr. Sabine Hauck as Chief Technical Officer
June 11, 2024 04:00 ET
|
AKAMPION
- Experienced biopharma professional focused on drug product development Munich, Germany - June 11, 2024 - Thermosome, a drug development company focused on targeted tumor therapies, today...
BellaSeno Receives Financial Support Through Queensland’s Industry Partnership Program
June 05, 2024 04:00 ET
|
AKAMPION
Funding to support establishment of the world´s first fully automated production facility for resorbable medical scaffolds based in AustraliaAI-driven, no-touch manufacturing to ensure highest...
selectION Announces Initiation of Phase 1b Clinical Trial Evaluating si-544 in Patients with Psoriasis Vulgaris or Psoriatic Arthritis
May 28, 2024 04:00 ET
|
AKAMPION
- New study follows completion of first-in-human Phase 1b trial in atopic dermatitis patients, in which selectION observed safety and tolerability of si-544 in the treatment of T cell autoimmunity ...